Press Release

United States Breast Cancer Therapeutics Market is Expected to be Dominated by Chemotherapy through 2028

The growing prevalence of breast cancer is expected to drive the growth of the United States breast cancer therapeutics market during the forecast period.

According to TechSci Research report, “United States Breast Cancer Therapeutics - By Region, Competition, Forecast, and Opportunities, 2018-2028, the United States breast cancer therapeutics market is anticipated to expand at a remarkable rate during the projected period, owing to several drivers such as rising incidence of breast cancer, improvements in cancer biology and pharmacology that support treatment development, rising R&D investment, the introduction of several diagnostic and screening programs, and favorable insurance and reimbursement policies.

In the US, breast cancer affects one in eight women at some point in their lifetime, making it the most prevalent type of cancer among women. The country has a sizable market for breast cancer therapeutics as a result, and it is expected that this market will expand over the coming years. The industry offers a variety of medical interventions, such as targeted therapies, hormone therapy, surgery, chemotherapy, and radiation therapy. The breast cancer therapeutics market in the United States is poised for further growth and innovation in the years to come due to ongoing research and development in the field of breast cancer therapy and a rising number of breast cancer patients.

The COVID-19 pandemic has significantly affected the breast cancer therapeutics market in the United States due to disruptions in the healthcare system, delay in cancer screenings and diagnosis, and shortages of some cancer medicines and medical supplies. Financial difficulties have been brought on by the pandemic for both patients and the healthcare sector. The implementation of digital technologies in healthcare has grown, resulting in higher efficiencies and better patient outcomes, and the industry has demonstrated its adaptability by putting new standards and safety measures in effect.

Browse over 30 market data Figures spread through 70 Pages and an in-depth TOC on "United States breast cancer therapeutics market"

The United States breast cancer therapeutics market can be segmented by therapy, end user, and region.

Based on therapy, the market can be segmented into chemotherapy, hormone therapy, immunotherapy, targeted therapy, and others. Due to its success in treating a variety of breast cancer cases, chemotherapy is predicted to dominate the US market for breast cancer therapeutics in the coming years. Chemotherapy is still the most popular form of treatment for breast cancer, despite the availability of alternatives such as radiation therapy, targeted therapy, and hormonal therapy. Chemotherapy medications have generated more interest in the market due to their promising performance in reducing tumor size and halting the spread of cancer cells. Additionally, this market segment is anticipated to grow in the near future due to ongoing improvements in chemotherapy drugs and personalized treatment methods.

In terms of end user, the market can be divided into hospitals, specialty clinics, ambulatory surgical centers, and others. Due to the increased demand for cutting-edge treatment options and the increasing prevalence of breast cancer, the hospital segment is anticipated to dominate the United States breast cancer therapeutics market n the next years. Hospitals provide a wide range of services such as diagnostic exams, surgeries, radiation therapy, and chemotherapy that are crucial in the treatment of breast cancer. Additionally, hospitals have state-of-the-art infrastructure and a staff of highly qualified medical specialists, allowing them to offer comprehensive care to patients with breast cancer. The hospital sector is anticipated to have significant development in the coming years due to the growing emphasis on the early detection and treatment of breast cancer.

Based on the region, the market can be classified into following categories, Northeast Region, Midwest Region, South Region, and West Region. Due to several factors, the Northeastern United States is likely to dominate the breast cancer treatments market in the coming years. The region has a greater incidence of breast cancer than other areas of the nation, which increases the need for treatment. The Northeast is also home to several prominent cancer centers and research organizations, which draw top talent and funding and help progress breast cancer treatments. Furthermore, the area has a higher concentration of medical facilities and insurance coverage, making patients' access to and cost of breast cancer treatment easier to manage. The Northeast is well-positioned to dominate the breast cancer treatments industry in the coming years due to an amalgamation of these features.

Major companies operating in United States breast cancer therapeutics market include:

  • AstraZeneca PLC
  • Eli Lilly and Company
  • Genentech
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Seattle Genetics, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Technology innovations, rising breast cancer prevalence, and increasing patient awareness have contributed to the tremendous rise of the United States breast cancer therapeutics market in recent years. However, the market also must deal with a number of challenges, such as exorbitant treatment costs, therapy side effects, and legal restrictions. However, the market is observing several trends, including the development of targeted therapies, the use of precision medicine, and the uptake of immunotherapy. Clinical studies and research are also being done to create novel cures and treatments for breast cancer, and businesses are spending money to patent their goods to obtain a competitive edge,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.

“United States Breast Cancer Therapeutics Market, By Therapy {Chemotherapy (Anthracyclines, Taxanes, Antimetabolites, and Others), Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Others), Immunotherapy, Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, and Others), and Others}, By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), By Region, Competition, Forecast & Opportunities, 2028”, has evaluated the future growth potential of the United States breast cancer therapeutics market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the United States breast cancer therapeutics market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News